Rituxan (rituximab)

P3, N=148, Recruiting, Cerium Pharmaceuticals, Inc. | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Apr 2027

Our findings support the existence of a subset of extranodal follicular lymphomas lacking an IGH::BCL2 rearrangement and highlight alternative pathways of lymphomagenesis with implications for classification and diagnosis. The identification of biallelic CREBBP mutations and a FOXO1 mutation provides molecular insight into extranodal FL biology, suggesting an overlap with nodal FL while supporting alternative oncogenic pathways in extranodal disease.

Apart from treating promptly the underlying trigger conditions, earlier incorporation of targeted anti-cytokine therapy such as anakinra is strongly favored these days. The cytotoxic etoposide shall be chiefly reserved for malignancy-associated HLH, including B-cell lymphomas, and refractory disease. Rituximab has led to superior outcomes when utilized to clear EBV-infected B-cell reservoirs...The anti-IFN-γ monoclonal antibody emapalumab has been approved for refractory HLH cases. The JAK 1/2 inhibitor ruxolitinib may prove useful in this space as well. The therapeutic arsenal is likely to evolve further in the direction of agents addressing specific pathophysiologic steps in asHLH. Targeting effector cytokines, their receptors, inflammasome pathways are promising future directions in asHLH therapeutics.

P3, N=250, Recruiting, University Hospital, Montpellier | Not yet recruiting --> Recruiting | Trial completion date: Sep 2030 --> Jun 2031 | Initiation date: Sep 2025 --> Jun 2026 | Trial primary completion date: Sep 2030 --> Jun 2031

The Zanubrutinib, Lenalidomide, and Rituximab regimen appears to have promising efficacy and acceptable safety in treating relapsed/refractory PCNSL, particularly for patients with the MCD subtype.

Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.

P2, N=120, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P2, N=43, Not yet recruiting, AIDS Malignancy Consortium

P2/3, N=960, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P1/2, N=460, Recruiting, Bristol-Myers Squibb | N=308 --> 460

Overall, most biologic therapies appear broadly reassuring with respect to overall malignancy, although non-melanoma skin cancer remains the most reproducible treatment-associated signal, particularly with tumor necrosis factor inhibitors and possibly abatacept. Rituximab retains a favorable profile in patients with prior lymphoproliferative disease, whereas IL-6 and IL-17/23 pathway inhibitors appear largely neutral or reassuring in currently available datasets...We further examine tumor-type-specific patterns, major modifiers of risk, and practical risk-stratified management strategies. The central clinical message is that malignancy safety in IMIA should be interpreted through an individualized framework that balances inflammatory control against oncologic vulnerability rather than through uniform class-based avoidance.

Kaplan-Meier analysis underscored the superior discriminatory capacity of the immune index in assessing the prognosis across various risk groups. The proposed immune index is a useful tool to predict the prognosis of DLBCL patients treated with R-CHOP immunochemotherapy in this study.